Esperion Therapeutics, Inc. clinical trials
Part of ARCHIMED, which holds 100% as of 2026-07-13. Source
The registry lists 24 studies whose lead sponsor is Esperion Therapeutics, Inc. 1 is recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 17, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 24studies on the registry
- 1open to participants now
Get an email when these change. Save the Esperion Therapeutics, Inc. studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
What it is testing
The drugs Esperion Therapeutics, Inc.’s studies test, most studies first; none is open now — 3 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- bempedoic acid7 in phase 30 open · 20
- 0 open · 1
- 0 open · 1
All 24 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 10
- 11
- 12
- 13
- 14
- 15
- 516
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Esperion Therapeutics, Inc.
- Esperion Therapeutics, Inc.24 studiesSame company
Something wrong?
Focus areas
Conditions Esperion Therapeutics, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 24 of 24.
- Bempedoic Acid Pregnancy Surveillance ProgramRecruitingNCT05103254
- A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)CompletedNCT05694260Phase 2
- Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating WomenCompletedNCT06021951Phase 4
- Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or PlaceboCompletedNCT02993406Phase 3
- Evaluation of ETC-1002 in Participants With Hypercholesterolemia and HypertensionCompletedNCT02178098Phase 2
- A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin IntoleranceCompletedNCT01751984Phase 2
- A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated TriglyceridesCompletedNCT01262638Phase 2
- Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)CompletedNCT03067441Phase 3
- Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)CompletedNCT03001076Phase 3
- Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)CompletedNCT02666664Phase 3
- Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular RiskCompletedNCT02991118Phase 3
- Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-CCompletedNCT03531905Phase 2
- A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin TherapyCompletedNCT03337308Phase 3
- Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-CCompletedNCT03051100Phase 2
- Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor TherapyCompletedNCT03193047Phase 2
- Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin IntolerantCompletedNCT02988115Phase 3
- A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 DiabetesCompletedNCT01607294Phase 2
- Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic PatientsCompletedNCT01941836Phase 2
- Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin TherapyCompletedNCT02072161Phase 2
- A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mgCompletedNCT02659397Phase 2
- A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With HypercholesterolemiaCompletedNCT01779453Phase 2
- A Multiple Ascending Dose Study of ETC-1002 in Healthy SubjectsCompletedNCT01485146Phase 1
- A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild DyslipidemiaCompletedNCT01105598Phase 1
- Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002CompletedNCT02044627Phase 1